Alaunos Therapeutics, Inc.
Alaunos Therapeutics, Inc. (TCRT) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · TCRT · as of Jun 8, 2026
Key Statistics
Explore Alaunos Therapeutics, Inc. Data
tcrt stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 10 · Buy rate: 10.0%
Competitors & Peers
tcrt competitorsTCRT
ADXN
AIM
CYCN
IBO
KTTAStock Performance
Full HistoryAbout Alaunos Therapeutics, Inc.
Alaunos Therapeutics, Inc. is an oncology company in the clinical trial phase, specializing in the creation of adoptive T-cell receptor (TCR) engineered therapies. Their pipeline includes a TCR Librar…
what is alaunos therapeutics, inc. · tcrt stock overview · alaunos therapeutics, inc. company profile · who is alaunos therapeutics, inc. ceo · tcrt NASDAQ · alaunos therapeutics, inc. headquarters · alaunos therapeutics, inc. business segments
About Stock Overview & Key Data
Alaunos Therapeutics, Inc. (TCRT) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Aug 24, 2005. As of the latest trading session, TCRT stock price is $2.00, with a market capitalization of $4.9M. The stock has returned -34.94% over the past 12 months and -37.15% year-to-date.
According to 10 Wall Street analysts, the consensus rating for Alaunos Therapeutics, Inc. stock is Hold, with an average 12-month price target of $—. In fiscal year 2025, Alaunos Therapeutics, Inc. reported revenue of $5000.00 and net income of -$4.2M. For detailed data — including Alaunos Therapeutics, Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Alaunos Therapeutics, Inc. (TCRT) stock price is $2.00. The stock is traded on NASDAQ under the ticker symbol TCRT. The 52-week range is $1.67 – $6.20.